Jefferies Group LLC upgraded shares of NewLink Genetics Corporation (NASDAQ:NLNK) from a hold rating to a buy rating in a report issued on Friday, September 8th, MarketBeat.com reports. The firm currently has $26.00 target price on the biotechnology company’s stock, up from their prior target price of $7.00.
NLNK has been the subject of several other reports. ValuEngine raised shares of NewLink Genetics Corporation from a strong sell rating to a sell rating in a report on Thursday, September 7th. Cantor Fitzgerald set a $32.00 target price on shares of NewLink Genetics Corporation and gave the company a buy rating in a research note on Sunday, June 4th. Zacks Investment Research raised shares of NewLink Genetics Corporation from a sell rating to a hold rating in a research note on Saturday, July 29th. Finally, Robert W. Baird lowered shares of NewLink Genetics Corporation from an outperform rating to a neutral rating and reduced their target price for the company from $25.00 to $8.00 in a research note on Thursday, June 8th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $24.17.
Shares of NewLink Genetics Corporation (NASDAQ:NLNK) traded down 3.94% during midday trading on Friday, hitting $12.67. The stock had a trading volume of 4,209,589 shares. NewLink Genetics Corporation has a 52-week low of $5.90 and a 52-week high of $25.17. The firm’s 50 day moving average price is $8.51 and its 200 day moving average price is $12.83. The firm’s market cap is $372.76 million.
NewLink Genetics Corporation (NASDAQ:NLNK) last released its earnings results on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.78) by $0.21. The company had revenue of $10.37 million during the quarter, compared to the consensus estimate of $2.65 million. NewLink Genetics Corporation had a negative net margin of 161.94% and a negative return on equity of 55.03%. On average, equities research analysts expect that NewLink Genetics Corporation will post ($2.82) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “NewLink Genetics Corporation (NASDAQ:NLNK) Upgraded at Jefferies Group LLC” was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://ledgergazette.com/2017/09/16/newlink-genetics-corporation-nlnk-upgraded-to-buy-at-jefferies-group-llc.html.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in NLNK. Teachers Advisors LLC raised its holdings in shares of NewLink Genetics Corporation by 2.8% in the 4th quarter. Teachers Advisors LLC now owns 201,807 shares of the biotechnology company’s stock worth $2,075,000 after purchasing an additional 5,500 shares in the last quarter. First Mercantile Trust Co. acquired a new stake in shares of NewLink Genetics Corporation during the first quarter valued at approximately $143,000. Russell Investments Group Ltd. acquired a new stake in shares of NewLink Genetics Corporation during the first quarter valued at approximately $978,000. Wells Fargo & Company MN raised its holdings in shares of NewLink Genetics Corporation by 3.0% during the first quarter. Wells Fargo & Company MN now owns 162,926 shares of the biotechnology company’s stock valued at $3,926,000 after acquiring an additional 4,701 shares during the period. Finally, First Trust Advisors LP acquired a new stake in shares of NewLink Genetics Corporation during the first quarter valued at approximately $620,000. Institutional investors and hedge funds own 54.78% of the company’s stock.
About NewLink Genetics Corporation
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.